Supplementation With Conjugated Linoleic Acid (CLA) as Complementary Therapy in the Management of Type 2 Diabetes Mellitus (Women's Diabetes Study)

Completed · Not applicable

Conditions studied: Diabetes Mellitus

In brief

The purpose of this study is to determine the role of CLA as a complementary therapy to improve body composition, glucose tolerance, fasting plasma glucose and insulin, and hemoglobinA1c (HbA1c) in subjects with type 2 diabetes mellitus (T2DM).

Key facts

Study ID

NCT01121471

Run by

Ohio State University

People needed

55

Starts

2004-12-01

Expected to finish

2006-11-01

Last updated by the study team

2010-05-12

Who can join

Age: 18 and older, up to 70. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• diagnosis of Type 2 diabetes mellitus
• obese
• postmenopausal
• HbA1c >6.49 and <14.1

You may not qualify if…

• use of tobacco
• substance abuse
• impaired cognitive function
• renal disease
• abnormal liver function
• gastrointestinal diseases
• use of exogenous insulin
• use of hormone replacement therapy currently or within past 6 months
• pacemaker/defibrillator

Where it is running

• The Ohio State University — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.